Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
up to 10 times as high as that of summary scoring. 3 We suggest that the authors reanalyze their data using psychometric methods, such as Rasch analysis, that are based on item-response theory; such methods significantly reduce measurement noise and produce interval-level measurement.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The text we found for this paper looks like another document, so the self-check wasn’t run.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
Kohler, S., Zeller, C., Iliev, H., & Kaspers, S. (2017) · Advances in Therapy · doi:10.1007/s12325-017-0573-0 · Cited by 195
The Primary Outcome Is Positive — Is That Good Enough?
Pocock, S., & Stone, G. W. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1601511 · Cited by 146
Neal, B. C., Perkovic, V., Mahaffey, K. W., Fulcher, G., Erondu, N., Desai, M. G., Shaw, W. C., Law, G., Walton, M. K., Rosenthal, N., et al. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12924 · Cited by 109
Plasma Viscosity Increase with Progression of Peripheral Arterial Atherosclerotic Disease
Poredoš, P., & Žižek, B. (1996) · Angiology · doi:10.1177/000331979604700306 · Cited by 38
Canagliflozin: Improving diabetes by making urine sweet
Vouyiouklis, M. (2013) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.80a.13053 · Cited by 17
Lafeuille, M., Grittner, A. M., Gravel, J., Bailey, R. A., Martin, S., Garber, L., Duh, M. S., & Lefèbvre, P. (2014) · Journal of Medical Economics · doi:10.3111/13696998.2014.980503 · Cited by 8
Research works printed but not linked: 1
- Ektare VU, 2014, Am J Manag Care, 20, S204
Cited by
Dapagliflozin in Patients with Chronic Kidney Disease
Heerspink, H. J. L., Stefánsson, B. V., Correa-Rotter, R., Chertow, G. M., Greene, T., Hou, F.-F., Mann, J. F. E., McMurray, J. J. V., Lindberg, M., Rossing, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2024816 · Cited by 5,618
Kleindorfer, D. O., Towfighi, A., Chaturvedi, S., Cockroft, K. M., Gutierrez, J., Lombardi-Hill, D., Kamel, H., Kernan, W. N., Kittner, S. J., Leira, E. C., et al. (2021) · Stroke · doi:10.1161/str.0000000000000375 · Cited by 3,237
Basic Mechanisms of Diabetic Heart Disease
Ritchie, R. H., & Abel, E. D. (2020) · Circulation Research · doi:10.1161/circresaha.120.315913 · Cited by 708
Diabetic vascular diseases: molecular mechanisms and therapeutic strategies
Li, Y., Liu, Y., Liu, S., Gao, M., Wang, W., Chen, K., Huang, L., & Liu, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01400-z · Cited by 704
Type 2 diabetes mellitus in adults: pathogenesis, prevention and therapy
Lu, X., Xie, Q., Pan, X., Zhang, R., Zhang, X., Peng, G., Zhang, Y., Shen, S., & Tong, N. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01951-9 · Cited by 665
Metadata
- Authors
- Fernández-Balsells, M., Sojo-Vega, L., & Ricart-Engel, W.
- Affiliations
- The George Institute for Global Health (AU)
- Spanish Biomedical Research Centre in Physiopathology of Obesity and Nutrition (ES)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-11-23
- Volume
- 377
- Issue
- 21
- Pages
- 2097-2099
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3086985336
- Semantic Scholar
- adcf6521fc16d253bb18514907bc3c2f6f7618a1
- Cited by
- 415
- References
- 8
- Citations by year
- 2026: 26 · 2025: 38 · 2024: 51 · 2023: 66 · 2022: 58 · 2021: 53 · 2020: 39 · 2019: 45 · 2018: 25 · 2017: 14
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- cc-by-nc-nd
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UNSWorks (University of New South Wales, Sydney, Australia) (submittedVersion, cc-by-nc-nd)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Funders
- British Heart Foundation (FS/13/34/30173)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Keywords
- canagliflozin, type 2 diabetes, cardiovascular events, renal events, SGLT2 inhibitors, Rasch analysis, item response theory, psychometric assessment, measurement noise
- MeSH terms
- Canagliflozin, Cardiovascular System, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Kidney
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. https://app.cochat.ai/papers/10.1056/nejmc1712572
- The paper
- Fernández-Balsells, M., Sojo-Vega, L., & Ricart-Engel, W. (2017). Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. New England Journal of Medicine. https://doi.org/10.1056/nejmc1712572
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.